MoneyWorks4Me

The company witnessed a 20.66% growth in the revenue at Rs. 55726.00 millions for the quarter ended September 2026 as compared to Rs. 46186.00 millions during the year-ago period.Profit for the quarter ended September 2026 rises by 79.65% to Rs. 6958.00  millions from Rs. 3873.00 millions.Operating profit for the quarter ended September 2026 rose to 13120.00 millions as compared to 8445.00 millions of corresponding quarter ended September 2025.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202609 202509 % Var 202609 202509 % Var 202603 202503 % Var
Sales 55726.00 46186.00 20.66 107092.00 124281.00 -13.83 205328.00 231154.00 -11.17
Other Income 2173.00 3642.00 -40.33 6577.00 7625.00 -13.74 16896.00 10034.00 68.39
PBIDT 13120.00 8445.00 55.36 21998.00 50798.00 -56.70 56070.00 83852.00 -33.13
Interest 770.00 334.00 130.54 1501.00 526.00 185.36 1483.00 1099.00 34.94
PBDT 12350.00 8111.00 52.26 20497.00 50272.00 -59.23 54587.00 82753.00 -34.04
Depreciation 3337.00 2948.00 13.20 6514.00 5746.00 13.37 12074.00 10394.00 16.16
PBT 9013.00 5163.00 74.57 13983.00 44526.00 -68.60 42513.00 72359.00 -41.25
TAX 2055.00 1290.00 59.30 2978.00 11041.00 -73.03 10316.00 18865.00 -45.32
Deferred Tax 86.00 513.00 -83.24 508.00 847.00 -40.02 1139.00 960.00 18.65
PAT 6958.00 3873.00 79.65 11005.00 33485.00 -67.13 32197.00 53494.00 -39.81
Equity 835.00 835.00 0.00 835.00 835.00 0.00 835.00 834.00 0.12
PBIDTM(%) 23.54 18.28 28.76 20.54 40.87 -49.74 27.31 36.28 -24.72
Peers
Company Name CMP
Sun Pharma. Inds. 1743.00
Dr. Reddys Labs. 1224.50
Cipla 1337.00
Lupin 1925.00
Zydus Lifesciences 1127.85
View more..